Sage Therapeutics initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of Sage Therapeutics with an Outperform rating and $61 price target. The analyst believes the company’s approach toward drug development related to neurosteroid biology could bring novel classes of compounds to disease markets in need of innovative alternatives. In addition, pipeline success could make Sage an attractive acquisition target, the analyst tells investors in a research note.